• Sunovion Pharmaceuticals Inc., of Marlborough, Mass., said the FDA accepted for review two supplemental new drug applications for use of atypical antipsychotic Latuda (lurasidone) as monotherapy and as adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).